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The sniffles, sneezes, aches, and pains of flu are a dreaded part of the winter season. The fear of
another deadly pandemic is ever imminent, and this issue’s Select looks at recent efforts to under-
stand this ever-shifting virus. From efforts aiming to predict its geographical spread to those that
elucidate the basic viral biology and host response, researchers are looking for new ways to stay
a step ahead of an influenza outbreak.CD8+ T cell number after boost is increased upon
interference with IL-12 in specific locations. Figure
courtesy of B. Slu¨tter and J. Harty.Clearing the Airway
We often catch the flu more than once, but do not always seem to receive
the benefit of a memory immune response. Given that prior exposure
to conserved epitopes on influenza A virus (IAV) proteins should leave
their imprint on the immune system, Slu¨tter et al. (2013) tested whether
boosting the number of IAV-protective CD8+ memory cells might help
to give a more powerful response to IAV. The authors used two distinct
methods for boosting based on Listeria monocytogenes (LM) and
vaccinia virus (VV) and found that the latter, which should stimulate a
distinct array of cytokines, gave better protection against IAV infection
in mice. The authors found that this response involved increased transit
of CD8+ cells to the airways specifically as well as upregulation
of CXCR3. Indeed, interfering with IL-12, which diminishes CXCR3
expression, specifically antagonized this effect, and neutralizing IL-12
increased the protective effect of boosted IAVmemory CD8+ cells. These
experiments suggest an avenue by which the response to IAV could be
increased without the use of annual vaccination and also outline a
mechanism by which the specific inflammatory response triggered by
the booster affects the degree of protection obtained.
Slu¨tter, B., et al. (2013). Immunity 39, 939–948.The crystal structure of IAV HA is shown (A) next
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RNA viruses are well-known for rapid mutation, but just how tolerant are
they to change? Heaton et. al (2013) have now tested this using a brute
force approach. The authors mutated a strain of influenza A virus (IAV)
by introducing a transposon and then removing it, leaving behind a short
insertion. The authors then looked for insertions that could be recovered
from infection of MDCK cells and found that these largely mapped to
two regions, hemagglutinin (HA) and nonstructural protein 1(NS1)/nuclear
export protein (NEP). They then repeated the HA experiments in a
competitive situation: infection of embryonated chick eggs. Again, the
authors found that HA was particularly tolerant of insertional mutagen-
esis. Indeed a particular subregion, the head domain of HA, seemed to
be able to continue to function even upon such large changes, in contrast
to the bulk of the IAV genome. IAV must balance selective pressure to
maintain functional proteins in a small, crowded genome against the
need to mutate quickly to evade host responses. The authors suggest
that this balance might be achieved by making particular regions more
flexible to mutation (in this case regions linked to host adaptation and
immune evasion).
Heaton N.S., et al. (2013). Proc. Natl. Acad. Sci. USA 110, 20248–20253.Cell 156, January 30, 2014 ª2014 Elsevier Inc. 381
‘‘Effective distance’’ of various destinations
from JFK airport, as derived by Brockmann and
Helbing (2013). Image courtesy of D. Brockmann.Contagious Model
Modeling how an epidemic will spread geographically is one way of
surveying and monitoring the threat from emerging infections. However,
modern global travel has taken the dynamics of disease spread away from
a simple reaction-diffusion model. For example, frequent traffic between a
pair of cities such as London and New Yorkmight make this long geographic
jump a quick hop for a new flu strain. In other words how ‘‘connected’’
two places are in a network is no longer so directly related to geographical
distance. Brockmann and Helbing (2013) have now developed a model of
disease spread based on ‘‘effective distance’’ between places. The effective
distance parameter reflects the relative number of people that travel
between given airports; in other words, it also incorporates traffic between
places. By building a network based on such ‘‘effective distance,’’ Brock-
mann and Helbing find that spread through the network follows a straight-
forward wave propagation pattern. Using this network, they were able to
reconstruct the 2009 H1N1 outbreak as well as the 2003 SARS epidemic.
The authors argue that the model can be applied to predict the arrival time
of future pandemics at a given location, giving valuable forewarning of
when a viral outbreak might actually arrive at a city’s doorstep.
Brockmann, D., and Helbing, D. (2013). Science 342, 1337–1342.Effect of AmphoB on IFITM-mediated restriction
of influenza A virus. Image courtesy of A. Brass.Attack of the Antifungal on the Antiviral
Host factors that fight the good fight and try to tamp down the onslaught of a
viral infection are called restriction factors. IFITM1, 2, and 3 are restriction
factors that target influenza A virus (IAV), but how they reduce replication
of the virus was not clear. Lin et al. (2013) now find that treating cells with
the antifungal, amphotericin B (AmphoB), removes the relationship between
high levels of IFITM3 expression and reduced IAV replication. Indeed
AmphoB reduces IAV restriction by both IFITM2 and 3. The authors quickly
ruled out straightforward mechanisms for this inhibition, such as alterations
in cellular ion flux through AmphoB’s pore-forming activity. Lin et al. then
moved to test the role of cholesterol, previously shown to bind AmphoB.
IFITMs were found to alter membrane fluidity and the authors suggest that
this is the mechanism by which viral replication is altered and the reason
that IFITMs are prone to inhibition by AmphoB. How might changes in
membrane fluidity reduce viral infectivity? The authors argue that IFITMs
might make host membranes less pliable and/or influence mobility of
viral-host receptor complexes, thus reducing viral entry, interesting
hypotheses for future testing. While Lin et al. (2013) used the effect of
AmphoB to probe the mechanism of IFITM action, their observations both
in vitro and in mice indicate that patients being treated with this antimycotic
might well be more susceptible to flu infection, an idea that invites clinical
follow up.
Lin, T.-Y., et al. (2013). Cell Rep. 5, 895–908.
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